A 12-week multicentre, randomised, double-blind, parallel group, Phase II pilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mg bid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtine citrate 400 mg bid (800 mg/d)
Read time: 1 mins
Last updated:26th Apr 2006
The primary objective is to evaluate the efficacy of cizolirtine citrate 200 mg twice daily, 300 mg twice daily, and 400 mg twice daily versus placebo in decreasing the frequency of incontinence episodes.
|Study start date||2006-04-26|